Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Salivary Gland Cancer
NCT01613768Phase 2Completed
- Sponsor
- University of Washington
- Start
- May 2012
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in salivary gland cancer (SGC), sponsored by University of Washington. Started May 2012; status: completed.
02
Drugs
eribulin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT01613768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613768.